ANAB — ANAPTYSBIO, INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1370053 ·
Last close
$45.61
Market Cap
$1.36B
52W High
$72.36
52W Low
$22.07
ADV30
440,010
Next earnings
2026-11-12
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 30,274,000 — 19,905,000 3,876,000 307,043,000 135,394,000 286,223,000
Mar 2026 25,556,000 — -34,637,000 -52,884,000 329,684,000 248,469,000 316,937,000
Dec 2025 108,249,000 — 66,901,000 49,614,000 364,395,000 138,196,000 327,185,000
Sep 2025 76,320,000 — 34,704,000 15,113,000 353,098,000 109,833,000 382,514,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$4,478,000
Investing CF
$248,168,000
Financing CF
$-102,814,000
CapEx
$-69,000
Dividends Paid
—
Buybacks
$-64,202,000
EPS Diluted TTM
$-1.08
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-825,443,000
Inventory
—
Receivables
$25,747,000
ST Investments
$37,986,000
EBIT TTM
$56,064,000
Pretax Income TTM
$-26,627,000
Interest Exp TTM
$82,691,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$60,042,000
EBITDA
$9,015,000
Free Cash Flow
$8,323,875
Enterprise Value
$1,484,398,464
Total Cash
$152,992,992
Total Debt
$262,386,000
Shares Out
29,729,847
Trailing EPS
$6.52
Book Value
$0.69
ROE
-114.6%
ROA
6.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 234,603,000 226,902,000 -13,232,000 364,395,000 327,185,000 37,210,000 19,697,000
Dec 2024 91,280,000 66,152,000 -145,231,000 483,834,000 412,966,000 70,868,000 -135,337,000
Dec 2023 17,157,000 -157,072,000 -163,619,000 452,389,000 364,286,000 88,103,000 -120,800,000
Dec 2022 10,287,000 -115,154,000 -128,724,000 610,383,000 348,280,000 262,103,000 -73,593,000

TTM Snapshot

Revenues TTM
$232,388,000
NetIncome TTM
$-26,787,000
OpCashFlow TTM
—
Assets (Latest)
$329,684,000
Forward EPS
$4.59

Max Pain — expiry 2027-02-19

max pain strike: $40.00 · spot: $47.06 · call oi: 977 · put oi: 289
Expected Move to 2027-02-19: ±$15.85 (33.68%) — implied range $31.21 – $62.91 · ATM straddle on $45.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TYRA Tyra Biosciences, Inc. $1.35B $19.57 —
NUVB Nuvation Bio Inc. $1.37B $3.90 —
OCUL OCULAR THERAPEUTIX, INC $1.32B $6.02 —
NBTX Nanobiotix S.A. $1.39B $27.45 —
DMRA Damora Therapeutics, Inc. $1.40B $22.56 —

News headlines (Yahoo Finance, 1h cache)

AnaptysBio, Inc. (ANAB) Misses Q3 Earnings and Revenue Estimates
2026-11-12 22:05 · Yahoo
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
2026-11-12 21:15 · Yahoo
AnaptysBio (ANAB) vs. PTCT and MIRM: Is the Market Missing the Value of Its Royalty Stream and Legal Upside?
2026-10-31 21:17 · Yahoo
Is AnaptysBio (ANAB) Undervalued Following Jemperli's Early FDA Approval?
2026-10-30 07:10 · Yahoo
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?
2026-10-27 13:00 · Yahoo
Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
2026-10-19 18:18 · Yahoo
Why This IPO Stock, An AnaptysBio Spinoff, Just Surged
2026-10-12 20:10 · Yahoo
AnaptysBio (ANAB) Could Be 49% Undervalued On Its Royalty Story
2026-10-09 04:29 · Yahoo
AnaptysBio (ANAB) Stock Looks Undervalued Even After A 273% Rise
2026-10-08 23:17 · Yahoo
AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
2026-09-26 03:38 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-18 18:56:28 2026-11-16 Ecor1 Capital, LLC Dir, 10% P - Purchase 45.98 374580 17224593